CI · Cigna Group · Financials
$275.28
-0.72 (-0.26%)
At close · Sep 18
Market Cap
$75.22B
Shares
264.24M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$274.9B
+11.2%
FY2025
Net Income
$5.96B
+73.5%
FY2025
Gross Margin
21.79%
-4.4pp
FY2025
Operating Margin
3.35%
-0.5pp
FY2025
Diluted EPS
$22.18
+83%
FY2025
Operating Cash Flow
$9.6B
-7.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $282.38B | $274.9B | $247.12B | $195.27B | $180.52B | $174.07BG | $160.4BG | $153.57B | $48.65B | $41.81B | $39.84B | |
| — | $38.04B | $40.26B | $46B | $44.24B | $39.92B | $41.15B | $42.63B | $39.71B | $36.11B | $32.49B | $30.82B | |
| — | $224.13B | $214.99B | $182.51B | $133.8B | $124.83B | $117.55B | $103.48B | $97.67B | $4.79B | $2.46B | $2.47B | |
| — | $58.25B | $59.91B | $64.61B | $61.46B | $55.68B | $56.52B | $56.92B | $55.9B | $43.86B | $39.35B | $37.37B | |
| — | — | 21.79% | 26.15% | 31.48% | 30.85% | 32.47% | 35.48% | 36.4% | 90.15% | 94.13% | 93.8% | |
| — | $14.16B | $14.62B | $14.84B | $14.82B | $13.17B | $13.01B | $14.07B | $14.05B | $11.93B | $10.03B | $9.79B | |
| — | $1.68B | $1.74B | $1.7B | $1.82B | $1.88B | $2B | $1.98B | $2.95B | $235M | $115M | $151M | |
| — | $2.72B | $2.78B | $2.78B | $3.04B | $2.94B | $2.92B | $2.8B | $3.65B | $695M | $566M | $610M | |
| — | $566M | — | $0 | $252M | $22M | $168M | — | — | — | — | — | |
| — | $9.96B | $9.2B | $9.42B | $8.54B | $8.45B | $7.94B | $8.15B | $8.08B | $4.16B | $3.94B | $3.09B | |
| — | — | 3.35% | 3.81% | 4.37% | 4.68% | 4.56% | 5.08% | 5.26% | 8.55% | 9.43% | 7.75% | |
| — | $12.68B | $11.98B | $12.19B | $11.57B | $11.39B | $10.86B | $10.96B | $11.73B | $4.86B | $4.51B | $3.7B | |
| — | -$1.42B | -$1.41B | -$1.44B | -$1.45B | -$1.23B | -$1.21B | -$1.44B | -$1.68B | -$498M | -$252M | -$278M | |
| — | $8.64B | $7.78B | $5.27B | $5.51B | $8.4B | $6.79B | $10.87B | $6.57B | $3.58B | $3.61B | $2.98B | |
| — | $1.66B | $1.49B | $1.49B | $141M | $1.62B | $1.37B | $2.38B | $1.45B | $935M | $1.37B | $1.14B | |
| — | $6.42B | $5.96B | $3.43B | $5.16B | $6.78B | $5.42B | $8.49B | $5.12B | $2.65B | $2.23B | $1.84B | |
| — | — | 2.17% | 1.39% | 2.64% | 3.76% | 3.11% | 5.29% | 3.33% | 5.44% | 5.34% | 4.63% | |
| — | $567M | $331M | $344M | $208M | $78M | $50M | $31M | $16M | $9M | -$5M | -$24M | |
| — | $6.15B | — | $3.43B | $5.16B | $6.7B | $5.37B | $8.46B | $5.1B | $2.64B | $2.24B | $1.87B | |
| — | $4.87B | $5.49B | $2.96B | $4.96B | $6.11B | $5.33B | $8.54B | $5.87B | $2.25B | $2.54B | $1.74B | |
| USD/shares | — | $24.30 | $22.33 | $12.25 | $17.57 | $21.66 | $15.89 | $23.17 | $13.58 | $10.69 | $8.92 | $7.31 |
| USD/shares | at least $30.45* | $24.17 | $22.18 | $12.12 | $17.39 | $21.41 | $15.75G | $22.96G | $13.44 | $10.54 | $8.77 | $7.19 |
| shares | — | — | 268.56M | 283.22M | 296.88M | 313.07M | 340.97M | 368.39M | 379.82M | 250.23M | 255.07M | 259.65M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2025: $37.52B in buybacks, $7.38B in dividends.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
0.35×
Peer median 0.42×
EV/EBIT
10.03×
Peer median 18.98×
P/E (TTM)
11.78×
Peer median 23.33×
Peer medians compare against the 7 similar-size Healthcare Plans companies (of 12 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Evernorth | $234,953,000,000 | $201,973,000,000 | $153,499,000,000 | $140,335,000,000 | $131,912,000,000 | $116,334,000,000 | $109,794,000,000 | $7,065,000,000 |
| Cigna Healthcare | $47,412,000,000 | $53,118,000,000 | $51,148,000,000 | $44,911,000,000 | $44,643,000,000 | $41,265,000,000 | $39,133,000,000 | — |
| All Other Segments | $674,000,000 | $828,000,000 | $596,000,000 | $2,263,000,000 | $3,989,000,000 | $8,446,000,000 | $8,215,000,000 | — |
| Group Disability and Other | — | — | — | — | — | $5,264,000,000 | $5,182,000,000 | $5,061,000,000 |
| International Markets | — | — | — | — | — | $6,007,000,000 | $5,659,000,000 | $5,323,000,000 |
| US Medical | — | — | — | — | — | $38,451,000,000 | $36,519,000,000 | $32,791,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $216,672,000,000 | $185,362,000,000 | $137,243,000,000 | $128,566,000,000 | $121,413,000,000 | $107,769,000,000 | $103,099,000,000 | $5,479,000,000 |
| Service Fees and Other Revenues | $16,921,000,000 | $14,790,000,000 | $12,619,000,000 | $10,881,000,000 | — | — | — | — |
| Service | $16,921,000,000 | $14,790,000,000 | $12,619,000,000 | $10,881,000,000 | $9,953,000,000 | $8,761,000,000 | $9,363,000,000 | $5,578,000,000 |
| Service Other | $696,000,000 | $584,000,000 | $210,000,000 | $168,000,000 | $188,000,000 | $254,000,000 | $157,000,000 | $20,000,000 |
| Home Delivery and Specialty | — | — | $65,732,000,000 | $61,283,000,000 | $54,391,000,000 | $49,906,000,000 | $49,226,000,000 | $3,997,000,000 |
| Network Pharmacy | — | — | $67,514,000,000 | $64,946,000,000 | $64,992,000,000 | $56,365,000,000 | $51,430,000,000 | $1,415,000,000 |
| Other Pharmacy | — | — | $9,047,000,000 | $6,753,000,000 | $6,428,000,000 | $5,403,000,000 | $4,900,000,000 | $67,000,000 |
| Service Fees | — | — | — | — | — | $8,532,000,000 | $9,229,000,000 | $5,558,000,000 |
Key facts
CIK
1739940
CUSIP
125523100
13F (30d)
41 filings
24 filers
Visit website
Investor relations